The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

June 23, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2021—Should we lump, or should we split? This was the interesting question posed during EULAR 2021 by Laura Coates, MBChB, MRCP, PhD, clinician-scientist and senior clinical research fellow at the National Institute for Health Research, University of Oxford, England, in her presentation on psoriatic arthritis (PsA) outcome assessments in clinical practice and trials.

You Might Also Like
  • A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis
  • Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms
  • Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
Explore This Issue
August 2021
Also By This Author
  • A World of Difference: Updates from the Global Rheumatology Summit

Why do we need outcome measures? Dr. Coates explained that, in seeking to know if the treatment of patients is achieving success, rheumatologists hope to identify the true status of disease activity. However, this proposition is unlike the treatment of hypertension, which can use blood pressure as the only relevant outcome measurement. No single test, laboratory or imaging study, or other variable can capture the totality of true disease activity in a condition like PsA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Each outcome measure used in PsA provides an individual perspective on a patient’s status. By putting all these outcomes together, the clinician gains a better sense of the global disease activity.

Next, Dr. Coates asked: What do we need to measure in PsA? Typically, outcomes of interest in rheumatology relate to degree of active inflammation, symptoms, functional impact on a patient’s ability to work or participate in exercise and leisure activities, and quality of life. Hard outcomes, such as bone or joint damage and degree of disability, are also important measures to the clinician and patient alike.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Coates’ third question: What matters to patients? Historically, many outcome measures have been developed by clinicians and researchers, with less direct input from patients themselves.

In 2017, a study from Tilett et al. ranked outcomes identified as important to patients with PsA and examined their representation in existing composite measures. The researchers collected input from 31 patients with PsA via seven meetings using nominal group technique, a structured method for brainstorming that encourages contributions from everyone and facilitates quick agreement on the relative importance of topics. The treatment outcomes ranked highest by patients were improvements in pain, fatigue, physical fitness, halting or slowing of damage and quality of life/well-being. The authors of the study point out that, in reviewing the existing composite measures for PsA, no single measure adequately identified all of these outcomes.1

According to Dr. Coates, because pain and fatigue are consistently regarded by patients as critical concerns, recent work has examined if these domains should be combined in outcome measurements.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

However, in a study of 141 patients with PsA, in which researchers used modified versions of the Composite Psoriatic Disease Activity Index (CPDAI) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Exercise (GRACE) measures, the addition of pain and fatigue did not improve the measures’ ability to detect disease status in terms of requiring treatment escalation.2

Most patients have evidence of disease activity across multiple domains, & it’s the constellation of multi-domain findings that defines a patient’s true disease activity, level of functioning & quality of life.

Individual vs. Composite Measures

On the subject of single vs. composite measures, Dr. Coates said PsA is a disease that can involve manifestations across multiple domains, including arthritis, enthesitis, dactylitis, axial spondyloarthritis, skin and nail disease, and common comorbid conditions, such as inflammatory bowel disease.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: EULAR, outcome, Outcome measures, PsA Resource Center, Psoriatic ArthritisIssue: August 2021

You Might Also Like:
  • A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis
  • Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms
  • Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
  • More Than Skin Deep: Insights into Clinical Challenges in Psoriatic Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)